Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02037256 · OUTCOME

>= 2 Fold Increase in Circulating PBSC's

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · Source last updated 2021-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 6 months

What was measured

Participants with \>= 2 fold increase in circulating PBSC's in blood and in apheresis collections in up to 4-days collection

Analysis population: Evaluable patients

Groups in this outcome

Group A: Bortezomib 1.3 mg/m2

Group A: Bortezomib 1.3 mg/m2 in the evening after completion of 5 day mobilization with G-CSF

Group B Bortezomib 1/3 mg/m2

Group B Bortezomib 1/3 mg/m2 on day 4 of 5 day GCSF mobilizati

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group A: Bortezomib 1.3 mg/m23
Group B Bortezomib 1/3 mg/m217

Reported measurements

Doubling
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Group A: Bortezomib 1.3 mg/m20Not reportedNot reportedNot reportedNot reported
Group B Bortezomib 1/3 mg/m24Not reportedNot reportedNot reportedNot reported
Less than doubling
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Group A: Bortezomib 1.3 mg/m23Not reportedNot reportedNot reportedNot reported
Group B Bortezomib 1/3 mg/m213Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        4
    title
    Doubling
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        13
    title
    Less than doubling
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      17
    units
    Participants
description
Participants with \>= 2 fold increase in circulating PBSC's in blood and in apheresis collections in up to 4-days collection
groups
  1. description
    Group A: Bortezomib 1.3 mg/m2 in the evening after completion of 5 day mobilization with G-CSF
    id
    OG000
    title
    Group A: Bortezomib 1.3 mg/m2
  2. description
    Group B Bortezomib 1/3 mg/m2 on day 4 of 5 day GCSF mobilizati
    id
    OG001
    title
    Group B Bortezomib 1/3 mg/m2
param Type
COUNT_OF_PARTICIPANTS
population Description
Evaluable patients
reporting Status
POSTED
time Frame
Up to 6 months
title
>= 2 Fold Increase in Circulating PBSC's
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice